| Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? | |
| | |
MedLine Citation:
|
PMID: 17005575 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A nested case-control study was conducted in order to examine whether dosing schedules of standard pyrazinamide-containing anti-tuberculosis (TB) treatment (standard treatment) might affect hepatotoxicity. The present authors retrospectively identified all patients with hepatitis using biochemical criteria from a cohort of 3,007 clinic patients who commenced anti-TB treatment from January 1 to June 30, 2001. Each case with hepatitis between 1-9 weeks post-TB treatment was compared using conditional logistic regression analysis with two controls selected randomly from patients without hepatitis in the same period and matched by sex, age and standard treatment. Impacts of sex and age were examined by logistic regression analysis of cases and patients without hepatitis. Hepatitis occurred in 167 patients, of whom 96 qualified as cases. A conditional logistic risk model identified hepatitis B surface antigen carriage as the only risk factor (odds ratio (95% confidence interval (CI)) 1.8 (1.1-3.1)). Logistic regression analysis showed that sex was nonsignificant but ageing increased the odds of hepatitis. The risk of hepatitis increased from 2.6% (1.9-3.5%) to 4.1% (3.2-5.3%) as age exceeded 49 yrs. Dosing schedules in the first 9 weeks have little impact on hepatotoxicity. If patients at risk of both hepatitis and relapse receive standard treatment, daily dosing is preferable. |
| | |
Authors:
|
K C Chang; C C Leung; W W Yew; C M Tam |
Related Documents
:
|
9517535 - Human immunodeficiency virus-related abdominal pain in south africa. aetiology, diagnos... 16438645 - Mycobacterium tuberculosis upregulates coreceptors ccr5 and cxcr4 while hiv modulates c... 7697015 - Mycobacterial infections in patients with aids in a low hiv prevalence area. 18205265 - Diagnosis of crohn's disease in india where tuberculosis is widely prevalent. 10801955 - Therapeutic application of zinc in human immunodeficiency virus against opportunistic i... 17668875 - Suppressor of cytokine signaling 3 (socs3) expression and hepatitis c virus-related chr... |
Publication Detail:
|
Type: Journal Article Date: 2006-09-27 |
Journal Detail:
|
Title: The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology Volume: 29 ISSN: 0903-1936 ISO Abbreviation: Eur. Respir. J. Publication Date: 2007 Feb |
Date Detail:
|
Created Date: 2007-01-31 Completed Date: 2007-04-20 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 8803460 Medline TA: Eur Respir J Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 347-51 Citation Subset: IM |
Affiliation:
|
Tuberculosis and Chest Service, Centre for Health Protection, Department of Health, Hong Kong, China. kc_chang@dh.gov.hk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Age Factors Aged Aged, 80 and over Antitubercular Agents / administration & dosage, adverse effects* Case-Control Studies Drug Administration Schedule Drug-Induced Liver Injury / epidemiology* Female Humans Liver / drug effects* Male Middle Aged Risk Tuberculosis, Pulmonary / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Antitubercular Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inhibitory effects of repeated hyperoxia on breathing in newborn mice.
Next Document: Sporadic and epidemic community legionellosis: two faces of the same illness.